A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts

Mackensen A, Hanssens L, Stelljes M, Bethge WA, Feuchtinger T, Kuenkele A, Aigner M, Yakushina A, Karitzky S, Holtkamp S, Assenmacher M, Jurk M, Rauser G, Schneider D, Rossig C (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Blood American Society of Hematology

Publisher: AMER SOC HEMATOLOGY

City/Town: WASHINGTON

Pages Range: 3836-+

Conference Proceedings Title: BLOOD

DOI: 10.1182/blood-2021-152452

Authors with CRIS profile

Andreas Mackensen Lehrstuhl für Innere Medizin V

Involved external institutions

Miltenyi Biotec GmbH DE Germany (DE) Universitätsklinikum Münster DE Germany (DE) Universitätsklinikum Tübingen DE Germany (DE) Ludwig-Maximilians-Universität (LMU) DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) Lentigen Technology US United States (USA) (US)

How to cite

APA:

Mackensen, A., Hanssens, L., Stelljes, M., Bethge, W.A., Feuchtinger, T., Kuenkele, A.,... Rossig, C. (2021). A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts. In BLOOD (pp. 3836-+). WASHINGTON: AMER SOC HEMATOLOGY.

MLA:

Mackensen, Andreas, et al. "A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts." Proceedings of the BLOOD WASHINGTON: AMER SOC HEMATOLOGY, 2021. 3836-+.

BibTeX: Download